Standard BioTools Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 389

Employees

  • Stock Symbol
  • LAB

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $0.62
  • (As of Monday Closing)

Standard BioTools General Information

Description

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Contact Information

Formerly Known As
Mycometrix, Fluidigm
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 50 Milk Street
  • 10th Floor
  • Boston, MA 02109
  • United States
+1 (650)
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 50 Milk Street
  • 10th Floor
  • Boston, MA 02109
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Standard BioTools Stock Performance

As of 16-Nov-2026, Standard BioTools’s stock price is $0.62. Its current market cap is $245M with 395M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.62 $0.70 $0.59 - $1.72 $245M 395M 1.17M $0.34

Standard BioTools Financials Summary

As of 30-Sep-2026, Standard BioTools has a trailing 12-month revenue of $84.4M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (157,888) 324,730 374,597 450,830
Revenue 84,430 85,331 91,008 106,340
EBITDA (82,517) (94,878) (90,419) (60,029)
Net Income 133,076 (74,896) (138,885) (74,656)
Total Assets 635,332 567,754 612,345 323,067
Total Debt 26,834 30,827 30,695 98,210
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Standard BioTools Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Standard BioTools‘s full profile, request access.

Request a free trial

Standard BioTools Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Standard BioTools‘s full profile, request access.

Request a free trial

Standard BioTools Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search fo
Discovery Tools (Healthcare)
Boston, MA
389 As of 2025

Pleasanton, CA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Standard BioTools Competitors (25)

One of Standard BioTools’s 25 competitors is 10x Genomics, a Formerly VC-backed company based in Pleasanton, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
10x Genomics Formerly VC-backed Pleasanton, CA
Illumina Formerly VC-backed San Diego, CA
Twist Bioscience Formerly VC-backed South San Francisco, CA
Sphere Fluidics Formerly VC-backed Cambridge, United Kingdom
ToolGen Formerly VC-backed Seoul, South Korea
You’re viewing 5 of 25 competitors. Get the full list »

Standard BioTools Patents

Standard BioTools Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025235792-A1 Compositions and methods for detecting allelic variants Pending 10-May-2024
WO-2025235787-A1 Methods and compositions for the analysis of nucleic acids Pending 10-May-2024
WO-2025235787-A8 Methods and compositions for the analysis of nucleic acids Pending 10-May-2024
EP-4612481-A2 High throughput optical imager Pending 03-Nov-2022
EP-4612481-A4 High throughput optical imager Pending 03-Nov-2022 G02B21/16
To view Standard BioTools’s complete patent history, request access »

Standard BioTools Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Standard BioTools Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Standard BioTools‘s full profile, request access.

Request a free trial

Standard BioTools Investments & Acquisitions (6)

Standard BioTools’s most recent deal was a Reverse Merger with Treeline Biosciences Holdings. The deal was made on 20-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Treeline Biosciences Holdings 20-Jul-2026 Reverse Merger Drug Discovery
Sengenics 21-Nov-2024 Merger/Acquisition Other Healthcare Services
SomaLogic Operating Company 05-Jan-2024 Merger/Acquisition Biotechnology
InstruNor 17-Jan-2020 Merger/Acquisition Diagnostic Equipment
DVS Sciences 13-Feb-2014 Merger/Acquisition Discovery Tools (Healthcare)
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Standard BioTools ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

21.62 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Standard BioTools’s complete esg history, request access »

Standard BioTools Exits (1)

Standard BioTools’s most recent exit was on 05-Jan-2024 from SomaLogic Operating Company. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
SomaLogic Operating Company 05-Jan-2024 Completed
To view Standard BioTools’s complete exits history, request access »

Standard BioTools Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Sengenics Boulder, CO 2008
Standard BioTools (Mass Cytometry Business) Boston, MA

Standard BioTools FAQs

  • When was Standard BioTools founded?

    Standard BioTools was founded in 1999.

  • Where is Standard BioTools headquartered?

    Standard BioTools is headquartered in Boston, MA.

  • What is the size of Standard BioTools?

    Standard BioTools has 389 total employees.

  • What industry is Standard BioTools in?

    Standard BioTools’s primary industry is Discovery Tools (Healthcare).

  • Is Standard BioTools a private or public company?

    Standard BioTools is a Public company.

  • What is Standard BioTools’s stock symbol?

    The ticker symbol for Standard BioTools is LAB.

  • What is the current stock price of Standard BioTools?

    As of 16-Nov-2026 the stock price of Standard BioTools is $0.62.

  • What is the current market cap of Standard BioTools?

    The current market capitalization of Standard BioTools is $245M.

  • What is Standard BioTools’s current revenue?

    The trailing twelve month revenue for Standard BioTools is $84.4M.

  • Who are Standard BioTools’s competitors?

    10x Genomics, Illumina, Twist Bioscience, Sphere Fluidics, and ToolGen are some of the 25 competitors of Standard BioTools.

  • What is Standard BioTools’s annual earnings per share (EPS)?

    Standard BioTools’s EPS for 12 months was $0.34.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process